Principal Investigator
Byron Lam
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231255
Clinical Trial Summary
A Phase Open-Label Dose Escalation Study to
Evaluate the Safety and Efficiency of AGTC-501
(rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized,
Controlled, Masked, Multi-center Study Comparing
Two Doses of AGTC-501 in Male Participants with
X-linked Retinitis Pigmentosa.
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other